Gene · 23765
Papers3,930
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,930
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO). | Adv Ther | 2025 | 39520657 | PubTator, text mining | PubMed |
| Bidirectional interaction between IL and 17A/IL-17RA pathway dysregulation and α-synuclein in the pathogenesis of Parkinson's disease. | Brain Behav Immun | 2025 | 39461385 | PubTator, text mining | PubMed |
| Sleep loss-induced oncogenic pathways are mediated via the neuron-specific interleukin-1 receptor accessory protein (AcPb). | Brain Behav Immun | 2025 | 39343106 | PubTator, text mining | PubMed |
| Erythrodermic Psoriasis: Excellent Management Avoiding Hospitalization. | Acta Dermatovenerol Croat | 2024 | 40657657 | PubTator, text mining | PubMed |
| Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations. | Front Immunol | 2024 | 39911581 | PubTator, text mining | PubMed |
Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial. | Front Immunol | 2024 | 39717777 | PubTator, text mining | PubMed |
| Inhibition of the Binding of Interleukin 17A with Interleukin 17A Receptor as a Treatment for Immune System and Inflammation Disorders, Cancer, and Neurodegenerative Diseases. | ACS Med Chem Lett | 2024 | 39691527 | PubTator, text mining | PubMed |
| Silencing SMAD4 inhibits inflammation and ferroptosis in asthma by blocking the IL-17A signaling pathway. | Respir Res | 2024 | 39643876 | PubTator, text mining | PubMed |
| Unraveling the Complexity of Chikungunya Virus Infection Immunological and Genetic Insights in Acute and Chronic Patients. | Genes (Basel) | 2024 | 39596565 | PubTator, text mining | PubMed |
| IL-17 signaling protects against Helicobacter pylori-induced gastric cancer. | Gut Microbes | 2024 | 39588838 | PubTator, text mining | PubMed |
| Targeting IL-17 and its receptors: A feasible way for natural herbal medicines to modulate fibroblast-like synoviocytes in rheumatoid arthritis. | Biochem Pharmacol | 2024 | 39481657 | PubTator, text mining | PubMed |
| Avelumab reduces STAT3 expression with effects on IL-17RA and CD15. | Dent Med Probl | 2024 | 39480959 | PubTator, text mining | PubMed |
| Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease. | J Clin Exp Hematop | 2024 | 39462545 | PubTator, text mining | PubMed |
| Eutopic and Ectopic Endometrial Interleukin-17 and Interleukin-17 Receptor Expression at the Endometrial-Myometrial Interface in Women with Adenomyosis: Possible Pathophysiology Implications. | Int J Mol Sci | 2024 | 39456936 | PubTator, text mining | PubMed |
| IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth. | Oncogene | 2024 | 39424989 | PubTator, text mining | PubMed |
Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'". | Am J Clin Dermatol | 2024 | 39405017 | PubTator, text mining | PubMed |
| Comment on "Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial". | Am J Clin Dermatol | 2024 | 39405016 | PubTator, text mining | PubMed |
| Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells. | Sci Rep | 2024 | 39384864 | PubTator, text mining | PubMed |
| Electroacupuncture Reduced Fibromyalgia-Pain-like Behavior through Inactivating Transient Receptor Potential V1 and Interleukin-17 in Intermittent Cold Stress Mice Model. | Brain Sci | 2024 | 39335365 | PubTator, text mining | PubMed |
| Effect of interleukin-17A on inflammatory mediator production in interleukin-1β-stimulated human dental pulp fibroblasts. | Eur J Oral Sci | 2024 | 39302740 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23765/papers?page=11